Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda and University College London agree neurodegenerative disease alliance

Takeda and University College London agree neurodegenerative disease alliance

14th October 2015

Takeda has announced a new collaboration with University College London that will focus on the development of new neurodegenerative disease therapies.

The partnership aims to identify and validate novel target genes for the treatment of neurodegenerative disease, with a focus on mechanistic approaches for isolating genes or signalling pathways that modify disease processes affecting neuronal health.

Initially running for a three-year period, the alliance will see the partners receive support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre.

Work will be carried out by Takeda's research unit in Cambridge. The deal represents one of the largest university partnerships formed by Takeda in the UK.

Dr Tetsuyuki Maruyama, general manager of Takeda's pharmaceutical research division, said: "This cooperation will help us to identify and validate novel therapeutic pathways in central nervous system diseases, which is one of Takeda's core therapeutic areas."

Takeda's Cambridge research unit is focused on target identification and drug discovery, with central nervous system conditions being one of its key focus areas.ADNFCR-8000103-ID-801803032-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.